Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norfloxacin vs Norfloxacin + Itopride for SBP Prophylaxis
NCT04161768Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Dec 2018
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of itopride in spontaneous bacterial peritonitis (SBP) (2 arms), sponsored by Tanta University. Primary endpoint: Number of bouts of recurrence during treatment at 6 months. Started Dec 2018; status: recruiting.
02
Drugs
itopride
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT04161768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161768.